How does vitamin D deficiency contribute to sarcopenia?

Label:chem

Topic
Sarcopenia is an age-related loss of muscle mass, strength, and function, and vitamin D deficiency is implicated in its pathophysiology.
Answer
Low serum 25-hydroxyvitamin D (25(OH)D) levels are associated with reduced muscle strength, physical performance, and increased sarcopenia prevalence. Mechanistically, vitamin D deficiency impairs muscle protein synthesis, disrupts calcium homeostasis, and increases oxidative stress and inflammation, exacerbating muscle deterioration.
Return to Home Chemical List
Knowledge you may be interested in
What is the role of vitamin D (Vit D) in skeletal muscle physiology? What is the role of CBG (cannabigerol) in bone healing? What are the effects of THC (tetrahydrocannabinol) on bone healing? What is the effect of CBD (cannabidiol) on bone healing? How do cannabinoids influence bone healing, and what are the specific roles of CB1 and CB2 receptors? What role does CaMKII play in GlyR clustering during early development? How does strychnine affect GlyR clustering, and what are the limitations of using strychnine? What is the primary function of gephyrin in inhibitory synapses, and how does it interact with GlyRs and GABAARs? Are there safety concerns with curcumin? What are the dosing strategies and bioavailability challenges for curcumin? What are the molecular mechanisms by which vitamin D affects muscle health? What is ferric derisomaltose (FDI), and what is its chemical role in research study? What is diazepam’s pharmacological role in modulating epileptiform activity, and at what concentration was it tested? Does combining diazepam with low-frequency rTMS produce additive or synergistic suppression of Ca²⁺ elevation? What is relugolix, and how does it function as a therapeutic agent in uterine diseases? How does relugolix monotherapy affect bone mineral density (BMD)? What strategy has been developed to mitigate relugolix-induced BMD loss? Does relugolix combination therapy preserve BMD over extended treatment periods? How do clinical outcomes compare between relugolix monotherapy and combination therapy? What evidence supports the efficacy of relugolix combination therapy in endometriosis?